Imaging Diagnostic Systems Submits Its Third Module to the FDA For the Pre-Market Approval Process

Submission Moves Company Closer to FDA Approval



Apr 17, 2001, 01:00 ET from Imaging Diagnostic Systems, Inc.

    FORT LAUDERDALE, Fla., April 17 /PRNewswire/ --
 Imaging Diagnostic Systems, Inc. (OTC Bulletin Board:   IMDS) announces the
 submission of Module 2, one of the most significant modules in the Pre-Market
 Approval (PMA) process, for its patented Computed Tomography Laser Mammography
 (CTLM)(R) system to the Food and Drug Administration (FDA).
     "This Module is significant because it deals with the proprietary computed
 algorithms (software) that are basically the heart of the CTLM(R) system.
 Working in conjunction with the laser source and the special array of
 detectors, the algorithms process the absorption of the light that passes
 through the breast tissue to create a three dimensional cross sectional view
 of the breast.  These three-dimensional images provide the radiologist with
 additional information that may assist with a more precise diagnosis," stated
 Richard Grable, CEO of Imaging Diagnostic Systems.
     Imaging Diagnostic Systems is seeking PreMarket Approval (PMA) from the
 Food and Drug Administration (FDA) for its CTLM(R) system to be used as an
 adjunct to mammography to aid in the detection of breast abnormalities.  Under
 the new Modular submission approach, the Company's PMA application has been
 divided into different modules, each of which will contain documentation
 required for the FDA review.  The Company has previously submitted two of the
 modules required and is currently completing the last two modules to be
 submitted.
     Imaging Diagnostic Systems, Inc. has developed the world's first patented
 laser-based breast imaging system that utilizes state-of-the-art laser
 technology and proprietary and patented algorithms to create three-dimensional
 cross sectional images of the breast.  The CTLM(R) is a non-invasive, painless
 examination that does not expose the patient to radiation or require breast
 compression.
     In conjunction with the provisions of the Safe Harbor section of the
 Private Securities Litigation Reform Act of 1995, this news release may
 contain forward-looking statements pertaining to future anticipated projected
 plans, performances and developments, as well as other statements relating
 future operations.  All such forward-looking statements are necessarily only
 estimates of future results, and there can be no assurance that actual results
 will not materially differ from expectation.  Further information on potential
 factors that could affect Imaging Diagnostic Systems, Inc. is included in the
 Company's filing with the Securities Exchange Commission.
     Interested persons are encouraged to visit the Company's Web site
 www.imds.com .
 
     Contact:
     Imaging Diagnostic Systems, Inc.
     Deborah O'Brien
     VP Corporate Communications
     954-581-9800
 
     Public Relations
     Margie Adelman
     561-620-7440
     Margie10@hotmail.com
 
 

SOURCE Imaging Diagnostic Systems, Inc.
    FORT LAUDERDALE, Fla., April 17 /PRNewswire/ --
 Imaging Diagnostic Systems, Inc. (OTC Bulletin Board:   IMDS) announces the
 submission of Module 2, one of the most significant modules in the Pre-Market
 Approval (PMA) process, for its patented Computed Tomography Laser Mammography
 (CTLM)(R) system to the Food and Drug Administration (FDA).
     "This Module is significant because it deals with the proprietary computed
 algorithms (software) that are basically the heart of the CTLM(R) system.
 Working in conjunction with the laser source and the special array of
 detectors, the algorithms process the absorption of the light that passes
 through the breast tissue to create a three dimensional cross sectional view
 of the breast.  These three-dimensional images provide the radiologist with
 additional information that may assist with a more precise diagnosis," stated
 Richard Grable, CEO of Imaging Diagnostic Systems.
     Imaging Diagnostic Systems is seeking PreMarket Approval (PMA) from the
 Food and Drug Administration (FDA) for its CTLM(R) system to be used as an
 adjunct to mammography to aid in the detection of breast abnormalities.  Under
 the new Modular submission approach, the Company's PMA application has been
 divided into different modules, each of which will contain documentation
 required for the FDA review.  The Company has previously submitted two of the
 modules required and is currently completing the last two modules to be
 submitted.
     Imaging Diagnostic Systems, Inc. has developed the world's first patented
 laser-based breast imaging system that utilizes state-of-the-art laser
 technology and proprietary and patented algorithms to create three-dimensional
 cross sectional images of the breast.  The CTLM(R) is a non-invasive, painless
 examination that does not expose the patient to radiation or require breast
 compression.
     In conjunction with the provisions of the Safe Harbor section of the
 Private Securities Litigation Reform Act of 1995, this news release may
 contain forward-looking statements pertaining to future anticipated projected
 plans, performances and developments, as well as other statements relating
 future operations.  All such forward-looking statements are necessarily only
 estimates of future results, and there can be no assurance that actual results
 will not materially differ from expectation.  Further information on potential
 factors that could affect Imaging Diagnostic Systems, Inc. is included in the
 Company's filing with the Securities Exchange Commission.
     Interested persons are encouraged to visit the Company's Web site
 www.imds.com .
 
     Contact:
     Imaging Diagnostic Systems, Inc.
     Deborah O'Brien
     VP Corporate Communications
     954-581-9800
 
     Public Relations
     Margie Adelman
     561-620-7440
     Margie10@hotmail.com
 
 SOURCE  Imaging Diagnostic Systems, Inc.